Menactra: A meningococcal conjugate vaccine

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1206, 2005, Pages 29-31

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY TITER; BACTERIAL STRAIN; BLOOD GROUP TYPING; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MENINGITIS; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; SHORT SURVEY; ADOLESCENT; ADULT; ARTICLE; DOSE RESPONSE; FEE; IMMUNOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEES, PHARMACEUTICAL; HUMANS; MENINGOCOCCAL VACCINES;

EID: 17944373016     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Immunization of college students against meningococcal disease. Med Lett Drugs Ther 2000; 42:69.
2. LH Harrison et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286:694.
3. NE Rosenstein et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894.
4. NE Rosenstein et al. Meningococcal disease. N Engl J Med 2001; 344:1378.
5. JU Ruggeberg and AJ Pollard. Meningococcal vaccines. Paediatr Drugs. 2004; 6:251.
6. ME Pichichero et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57.
7. NE Rosenstein et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998; 279:435.
8. PG De Wals et al. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292:2491.
9. MC Maiden et al. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829.
10. E Miller et al. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 suppl 1:S58.
11. ME Ramsay et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365.
12. DM Granoff and SL Harris. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004; 23:490.
13. M Rennels et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429.
14. R Borrow et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002; 186:1353.
15. CL Trotter et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365.
16. M Mitka. New vaccine should ease meningitis fears. JAMA 2005; 293:1433.